C3.ai Earns ‘Reduce’ Consensus with $21.92 Mean Price Target
C3.ai has been rated “Reduce” by 15 brokerages—five sell, seven hold, two buy and one strong-buy—with an average 12-month price target of $21.92. In Q4 the company reported a loss per share of $0.25, beating estimates by $0.08, while revenue declined 20.3% year-over-year to $75.15 million.
1. Brokerages Issue Consensus “Reduce” Rating for C3.ai
Fifteen brokerages covering C3.ai have collectively assigned a consensus recommendation of “Reduce,” with five firms issuing sell ratings, seven assigning holds and two recommending buys alongside one strong‐buy designation. Over the past year, analysts’ average 12-month price target stands at $21.92, reflecting a 41% discount to the company’s peak valuation last spring. Notable revisions include UBS Group’s upward adjustment from $16 to $17 while maintaining a neutral view, contrasted by Canaccord Genuity and Needham both reaffirming hold ratings on December 4. Wedbush remains the most optimistic large‐cap broker, retaining an outperform stance with a $20 target, whereas Weiss Ratings continues to flag downside risk with a sell (D–) opinion dating to October 8.
2. Insider Dispositions Highlight Management’s Reduced Exposure
Company filings show C3.ai’s CEO divested 234,918 shares on December 31 at an average of $13.56, reducing his stake by 20.3% to 924,074 shares held directly. Earlier, Chairman Thomas Siebel sold 554,802 shares on October 14 at approximately $18.82, trimming his position by 22.1% to 1.96 million shares. Combined insider sales over the past three months totaled nearly 1.95 million shares for proceeds of $30.8 million, pushing insider ownership down to 26.5% of total common stock. These transactions have been disclosed in SEC filings and suggest senior leadership is capitalizing on market valuations rather than signaling fresh insider accumulation.
3. Quarterly Results Show Narrow Beat and Continued Revenue Contraction
For the quarter ended December 3, C3.ai reported revenue of $75.2 million, up modestly when adjusted for FX but down 20.3% year-over-year, slightly surpassing the consensus forecast of $74.9 million. Adjusted loss per share was $0.25, a $0.08 improvement versus the consensus estimate of a $0.33 loss. Despite beating earnings expectations, the company’s net margin remained deeply negative at 108%, and return on equity was a negative 46.5%. Management’s outlook projects a full-year adjusted loss per share of $2.44, underscoring continued investment in product development even as top-line growth stalls. Institutional investors currently hold 38.96% of shares, indicating cautious but substantial long-term positioning by large funds.